Antidote

NOVEMBER 15, 2024

Looking toward 2025, clinical trial sponsors must plan now and rethink their patient recruitment strategies to stay ahead of evolving technologies, regulations, and shifting patient expectations.

Clinical Trials 52

Clinical Trials Trials Regulations 52

Crown Bioscience

NOVEMBER 14, 2024

As we approach 2025, biomarker analysis in the preclinical stage is poised for transformative changes, driven by advances in technology, data science, and evolving regulatory frameworks.

Clinical Research 52

Clinical Research Research Science 52

Fierce BioTech

OCTOBER 15, 2024

A Pharma Marketers' Roadmap to Data Privacy Compliance : Are You Ready for 2025? swheeler Tue, 10/15/2024 - 19:53 Thu, 11/21/2024 - 13:00 Resource Type Webinar Ben Chapman Duration 60 minutes Join for an insightful webinar on the evolving privacy landscape impacting pharma marketers in 2025.

Compliance 52

Compliance Marketing Regulations 52

Conversations in Drug Development Trends

NOVEMBER 5, 2024

In preparation for World Orphan Drug Congress Europe, we interviewed Nathan Chadwick, Senior Director, Therapeutic Strategy Lead, Rare Disease, and Derek Ansel, MS, LCGC, Vice President, Therapeutic Strategy Lead, Rare Disease, to hear their insights into the current progress in rare disease research and their hopes for 2025.

Disease 52

Disease Clinical Trials Therapies Clinical Research 52

Fierce BioTech

OCTOBER 17, 2024

Takeaways: A closer look at how pharmaceutical marketers can enhance 2025 media strategies and planning by leveraging more sophisticated audience profiling techniques. The importance of balancing privacy with the need for deeper insights into patient behaviors and demographics in an increasingly crowded media environment.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Treatment Marketing 52

FDA Law Blog: Biosimilars

SEPTEMBER 4, 2024

HP&M”) is proud to announce that 16 of the Firm’s attorneys have been selected to the 2025 edition of The Best Lawyers in America®. Hyman has been rightfully chosen as a 2025 “Lawyer of the Year.” Hyman, Phelps & McNamara, P.C. (“HP&M”) Founding Director Paul M. Additionally, Kalie E. Richardson, James E.

FDA 52

FDA 52

H1 Blog

OCTOBER 30, 2023

By 2025, we can anticipate pretty significant shifts as AI continues to advance and integrate into various processes within the healthcare ecosystem. We predict that by 2025 we will see more widespread use of AI in recruiting patients for clinical trials. Here are 4 predictions for how life sciences companies might be using AI by then.

Science 59

Science Clinical Trials Trials Engineering 59

Drug Channels

APRIL 8, 2024

This unique, new event will be held from March 17 to 19, 2025, at the Turnberry Resort and Spa in Miami. I am pleased to announce the inaugural Drug Channels Leadership Forum !

Pharmacy 72

Pharmacy Drugs Government Pharmaceuticals 72

keypoint

AUGUST 21, 2024

Conferences in our 2025 Health Equity Series will feature programming that showcases how scientists are bringing molecular, cellular, and genetic approaches to bear on health equity research and outcomes. This year we are expanding this pilot program to include over a dozen conferences in our portfolio!

Disease 40

Disease Research 40

Agency IQ

JULY 22, 2024

Updated EUDAMED roadmap projects mandatory use of some processes as early as December 2025 The new EUDAMED roadmap includes updates accounting for the recent amendments to the European medical device and diagnostics regulations, which allow for a phased rollout of the different functional modules of the database. OJEU) around July 2025.

Regulations 40

Regulations Marketing Clinical Trials Trials 40

BioPharma Drive: Drug Pricing

OCTOBER 18, 2024

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.

Hospitals 107

Hospitals Disease Trials Treatment 107

Drugs.com

OCTOBER 27, 2024

28, 2025 -- Halloween is meant to be a spooky season, but it can be downright terrifying to someone suffering from Alzheimer’s disease or dementia.“Halloween MONDAY, Oct. Halloween is full of scary sights and frightful sounds that create additional cha.

Disease 98

Disease 98

DS in Pharmatics

JULY 29, 2024

DS Inpharmatics, a pharmaceutical quality expert, emphasizes proactive vendor GxP compliance evaluation to ensure supply chain integrity for the 2024 audits.

Compliance 52

Compliance Pharmaceuticals 52

Drugs.com

JULY 25, 2024

THURSDAY, July 25, 2025 -- Synthetic antibiotics that attack bacteria in two directions at once could be the solution for combatting antimicrobial-resistant bugs, a new study claims.These dual-action antibiotics, called macrolones, disrupt.

116

116

BioPharma Drive: Drug Pricing

JULY 31, 2024

Launched last September, the company is working on a treatment for alpha-1 antitrypsin deficiency, which it said could enter the clinic in 2025.

RNA 114

RNA Treatment 114

BioPharma Drive: Drug Pricing

AUGUST 21, 2024

Pharmaceuticals like the in-demand GLP-1 drugs for obesity are expected to drive increases in healthcare spending in 2025, per a new employer survey.

Pharmacy 105

Pharmacy Pharmaceuticals Drugs 105

Agency IQ

JULY 22, 2024

BY COREY JASEPH, MS, RAC The new EUDAMED roadmap includes updates accounting for the recent amendments to the European medical device and diagnostics regulations, which allow for a phased rollout of the different functional modules of the database.

Regulations 59

Regulations 59

KIF1A

NOVEMBER 1, 2024

2025 KAND Family & Scientific Engagement Conference We’re excited to announce the official dates for our 2025 KAND Conference! Mark your calendars for July 25-26, 2025, and plan to join us in Boston. Visit our 2025 KAND Conference webpage for all the details, links, and information as it is available. SAVE the DATE!

Treatment 52

Treatment Medical Schools Research Disease 52

BioPharma Drive: Drug Pricing

JUNE 10, 2024

Positive results from the trial could position Moderna to bring the two-in-one vaccine to market in 2025.

Vaccine 117

Vaccine Trials Marketing 117

thought leadership

NOVEMBER 12, 2024

A New Era for Pharmaceutical Development and Licensing in the UK The Windsor Framework , set to be implemented from January 1, 2025, marks a significant shift in the regulatory landscape for pharmaceutical development and licensing in the United Kingdom (UK).

Licensing 52

Licensing Licensing Pharmaceuticals Production 52

Quanticate

SEPTEMBER 13, 2024

In our article, we cover the key trends that have been shaping clinical trials so far in 2024, and those that are predicted to continue into 2025.

Clinical Trials 84

Clinical Trials Trials Drug Development Treatment 84

Drugs.com

MARCH 26, 2024

TUESDAY, March 26, 2025 -- A protein that shuts down immune cells in the lungs could be key to a new treatment for asthma attacks, a new report says.The naturally occurring protein, called Piezo1, prevents a type of immune cell called type 2 innate.

Research 98

Research Treatment 98

Perficient: Drug Development

OCTOBER 31, 2024

The Federal Deposit Insurance Corporation (“FDIC”) recently announced that it is providing financial institutions additional time to get new process and systems in place by extending the compliance date for the new FDIC signage and advertising rule (Part 328, subpart A) from January 1, 2025, to May 1, 2025.

Compliance 52

Compliance Production 52

BioPharma Drive: Drug Pricing

OCTOBER 4, 2023

The company is planning to start a Phase 3 trial of the vaccine this year, and is targeting a regulatory approval in 2025.

Vaccine 111

Vaccine Trials 111

thought leadership

OCTOBER 31, 2024

Clinical trials registered under the previous EU Clinical Trials Directive (EU-CTD), that are expected to continue after January 30, 2025, are now called Transitional Trials, and these are also required to be transitioned to EU-CTR by the deadline.

Clinical Trials 59

Clinical Trials Regulations Trials Compliance 59

FDA Law Blog: Biosimilars

SEPTEMBER 11, 2024

Last week’s guidance is featured on FDA’s new nitrosamines webpage and recommends that manufacturers implement revisions to control measures by August 1, 2025, noting that manufacturers and sponsors of approved products were expected to complete evaluations for small molecule nitrosamines last year.

Small Molecule 104

Small Molecule FDA Production Drugs 104

Agency IQ

JULY 22, 2024

Pigment Violet 29; Regulation Under the Toxic Substances Control Act (TSCA) November 2024 August 2024 Spring 2021 Proposed Rule Stage National Emission Standards for Hazardous Air Pollutants: Chemical Manufacturing Area Source Technology Review November 2024 TBD Fall 2019 Final Rule Stage Federal Plan Requirements for Commercial and Industrial Solid (..)

Regulations 40

Regulations Production Engineering International 40

thought leadership

MAY 7, 2024

Are You Ready for Mandatory EU Health Technology Assessment Regulation (HTAR) Implementation Beginning January 2025? Pharmaceutical companies need to be prepared for the new European Health Technology Assessment Regulation (HTAR), which will take effect in January 2025.

Pharmaceutical Companies 59

Pharmaceutical Companies International Regulations Pharmaceuticals 59

The Pharma Data

MAY 18, 2021

It is anticipated that the combined moves will see over a billion toothpaste tubes per year become recyclable by 2025. We have made the commitment that 100% of our product packaging will be recyclable or reusable, where quality and safety permits, by 2025.This

Packaging 40

Packaging Science Marketing Production 40

Science Daily: Pharmacology News

JANUARY 19, 2024

The new insulin is ready to be tested on humans in 2025. The medication that can be taken orally has already been tested on baboons, in which it was found to lower the blood sugar levels without causing hypoglycemia. If all goes well, diabetics are facing an easier life without injections.

Research 98

Research 98

Fierce BioTech

SEPTEMBER 30, 2024

llam Mon, 09/30/2024 - 18:25 Resource Type Questex Event FBW Clinical Topics.png Tue, 10/07/2025 - 07:30 Content Channel Landing Page Url LEARN MORE Byline Presented by: Fierce Biotech & Fierce Pharma

Pharma Companies 52

Pharma Companies Drug Development Marketing Drugs 52

Fierce BioTech

SEPTEMBER 30, 2024

llam Mon, 09/30/2024 - 17:44 Resource Type Questex Event Fierce Pharma Engage Logo Color.png Tue, 04/29/2025 - 08:00 Content Channel Landing Page Url LEARN MORE Byline Presented by: Fierce Pharma & Fierce Biotech

Marketing 52

Marketing 52

Fierce BioTech

SEPTEMBER 30, 2024

llam Mon, 09/30/2024 - 18:06 Resource Type Questex Event FiercePharmaWeekAudience.jpg Mon, 09/08/2025 - 08:00 Content Channel Landing Page Url LEARN MORE Byline Presented by: Fierce Pharma & Fierce Biotech

Science 52

Science Production Marketing 52

Drugs.com

JULY 12, 2024

FRIDAY, July 12, 2025 -- Almost 10% of women who get COVID during pregnancy develop long-lasting symptoms, and a new study suggests doctors may be overlooking them."I I doubt most obstetric clinicians are as aware of Long COVID as perhaps we should.

Doctors 52

Doctors 52

SCIENMAG: Medicine & Health

MARCH 19, 2024

Credit: IVI IVI will complete the technology transfer by 2025 Oral Cholera Vaccine to be manufactured by Biological E.

Vaccine 82

Vaccine Marketing International 82

Agency IQ

AUGUST 23, 2024

AgencyIQ summarizes the noteworthy changes in the updates to several documents designed to help sponsors and other entities involved with clinical trials to transition to the Clinical Trials Information System (CTIS) on January 30, 2025. Fill out the form to read the full article.

Clinical Trials 52

Clinical Trials Trials 52

Fierce BioTech

AUGUST 26, 2024

Pharma Marketing Trends: Key Takeaways from Digital Pharma East 2024 swheeler Mon, 08/26/2024 - 14:05 Thu, 09/26/2024 - 13:00 Resource Type Webinar Stephanie Butler Promotion Start Tue, 08/27/2024 - 14:15 Promotion End Thu, 02/27/2025 - 14:15 Duration 60 minutes Did you miss the buzz at Digital Pharma East 2024? Click here to login.

Marketing 52

Marketing Disease 52